Summit Therapeutics Inc. Common Stock (SMMT) Stock Price

SMMTStock

$14.63−33.41%52W

Market Cap$11.67B

P/E—

PEG Ratio—

Div yield—

Beta-1.65

SMMT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-39.74%

Price vs S&P 500 (4W)-12.11%

VGM Score28.15

Book Value / Share (Quarterly)$0.79

P/TBV (Annual)6.75x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.58

Price vs S&P 500 (YTD)-28.28%

Net Profit Margin (TTM)-9027.08%

EPS (TTM)$-1.12

10-Day Avg Trading Volume5.65M

EPS Excl Extra (TTM)$-1.12

EPS (Annual)$-0.31

ROI (Annual)-56.93%

Net Profit Margin (5Y Avg)-5207.57%

Cash / Share (Quarterly)$0.87

ROA (Last FY)-50.81%

EBITD / Share (TTM)$-1.14

ROE (5Y Avg)-216.65%

Operating Margin (TTM)-8108.33%

Cash Flow / Share (Annual)$-0.42

P/B Ratio18.57x

P/B Ratio (Quarterly)17.95x

Net Income / Employee (Annual)$-835,200

EV / Revenue (TTM)11750.66x

Net Interest Coverage (TTM)-121.35x

ROA (TTM)-141.92%

EPS Incl Extra (Annual)$-0.31

Current Ratio (Annual)9.87x

Quick Ratio (Quarterly)6.67x

3-Month Avg Trading Volume5.81M

52-Week Price Return-33.41%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.60

P/S Ratio (Annual)16478.87x

Asset Turnover (Annual)0.00x

52-Week High$29.23

Operating Margin (5Y Avg)-4960.39%

EPS Excl Extra (Annual)$-0.31

CapEx CAGR (5Y)9.36%

26-Week Price Return-29.83%

Quick Ratio (Annual)9.78x

13-Week Price Return5.94%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.96x

Enterprise Value$11.28B

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-2.46%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-11095.77%

Cash / Share (Annual)$0.92

3-Month Return Std Dev71.03%

Net Income / Employee (TTM)$-3,230,500

ROE (Last FY)-56.93%

Net Interest Coverage (Annual)-67.22x

EPS Basic Excl Extra (Annual)$-0.31

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.12

Receivables Turnover (Annual)0.00x

ROI (TTM)-168.93%

P/S Ratio (TTM)12187.50x

Pretax Margin (5Y Avg)-5211.66%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.60

Price vs S&P 500 (52W)-48.94%

Year-to-Date Return-16.35%

5-Day Price Return-14.59%

EPS Normalized (Annual)$-0.31

ROA (5Y Avg)-99.04%

Net Profit Margin (Annual)-11095.77%

Month-to-Date Return-13.48%

Cash Flow / Share (TTM)$-1.21

EBITD / Share (Annual)$-0.31

Operating Margin (Annual)-10153.52%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-117.59%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.12

P/TBV (Quarterly)6.75x

P/B Ratio (Annual)19.76x

Pretax Margin (TTM)-9027.08%

Book Value / Share (Annual)$0.85

Price vs S&P 500 (13W)3.25%

Beta-1.65x

Revenue / Share (TTM)$0.00

ROE (TTM)-168.93%

52-Week Low$12.07

vGradeF

mGradeC

vgmGradeD

SMMT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 23, 2026	-$0.21	-$0.21	+2.05%(+$0.00)
Q1 2026	Apr 30, 2026	-$0.21	-$0.18	+14.25%(+$0.03)
Q4 2025	Feb 23, 2026	-$0.01	-$0.21	-1386.30%(-$0.20)
Q3 2025	Oct 20, 2025	-$0.04	-$0.23	-429.27%(-$0.19)
Q2 2025	Aug 11, 2025	-$0.07	-$0.57	-721.43%(-$0.50)

SMMT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.75

3.88

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Summit Therapeutics Inc. Common Stock

Summit Therapeutics is a biopharmaceutical company focused on developing novel antibiotics for serious infectious diseases. Its lead product candidate, ridinilazole, is an orally administered antibiotic designed to treat Clostridioides difficile infections (CDI). The company operates in the United States and United Kingdom.

SMMT Next Earnings Report

Report dateOct 19, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.21

Revenue estimate$54,000

Also reporting on Oct 19, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for October 2026

Companies in Related Industries

EXELExelixis IncBiological Products
HALOHalozyme Therapeutics, Inc.Biological Products
NBIXNeurocrine Biosciences IncBiological Products
RPMRPM International, Inc.Paints & Coatings
TECHBio-Techne Corp.Biological Products
ALBAlbemarle CorporationPlastics & Resins
RGENRepligen CorpBiological Products
CLXClorox CompanyCleaning & Polishing Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$12.07

High$29.23